Conclusion:
Immune targeted therapies can be a promising outlook for the treatment
of COVID-19 infection. Until now, antiviral agents were not particularly
successful in controlling this massive pandemic, and there is also
strong evidence of dysregulated immune responses during this infection.
So, agents with immunomodulatory properties that can reinforce the
immune system to clear the virus by itself can take into consideration.
The CD200: CD200-R inhibitors, IFN I & III, and immune checkpoint
inhibitors might be the plausible immunomodulator options.
Clinical decisions about using these agents must be based on the
patient’s immunological status, cost & availability, and specifically,
the results of ongoing clinical studies on their safety and efficacy for
the current purpose.
Fig.1 shows a summary of possible immune targeted therapies for COVID-19
infection.